Cargando…

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA

AIM: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, and is associated with high healthcare burden. We evaluated the cost–effectiveness of pegcetacoplan, a proximal complement-3 inhibitor (C3i), compared with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fishman, Jesse, Wilson, Koo, Drzewiecka, Aleksandra, Pochopień, Michał, Dingli, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Becaris Publishing Ltd 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690430/ https://www.ncbi.nlm.nih.gov/pubmed/37655691 http://dx.doi.org/10.57264/cer-2023-0055

Ejemplares similares

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
por: Wong, Raymond, et al.
Publicado: (2023)

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022)

Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
por: Wong, Raymond, et al.
Publicado: (2023)

Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022)

P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Wong, R., et al.
Publicado: (2022)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
por: Bogdanovic, Andrija, et al.
Publicado: (2023)

P839: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS
por: Weitz, I., et al.
Publicado: (2022)

Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria
por: Mon Père, Nathaniel, et al.
Publicado: (2018)

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment
por: Fishman, Jesse, et al.
Publicado: (2023)

P838: PEGCETACOPLAN RAPIDLY STABILIZES COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA EXPERIENCING HEMOLYSIS WITH ACUTE HEMOGLOBIN DECREASES; PRINCE TRIAL POST HOC ANALYSIS
por: Wong, R., et al.
Publicado: (2022)

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A
Publicado: (2022)

Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
por: Sharma, Vivek, et al.
Publicado: (2023)

P757: INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Fishman, Jesse, et al.
Publicado: (2023)

The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
por: Bektas, Meryem, et al.
Publicado: (2020)

P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS
por: Kelly, Richard, et al.
Publicado: (2023)

PB2043: CLINICAL EFFECTIVENESS, TREATMENT USE, SATISFACTION AND IMPACT ON QUALITY-OF-LIFE OF PEGCETACOPLAN TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH).
por: Wilson, Koo, et al.
Publicado: (2023)

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
por: Risitano, Antonio M., et al.
Publicado: (2020)

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
por: Patir, Pusem, et al.
Publicado: (2015)

Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria
por: Ram, R., et al.
Publicado: (2017)

Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
por: Colden, Melissa A., et al.
Publicado: (2022)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Early Mortality in Paroxysmal Nocturnal Hemoglobinuria
por: Sørensen, Anne Lykke, et al.
Publicado: (2023)

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation
por: Alashkar, Ferras, et al.
Publicado: (2020)

Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
por: Gembillo, Guido, et al.
Publicado: (2020)

Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
por: Risitano, A., et al.
Publicado: (2022)

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
por: Szer, Jeff, et al.
Publicado: (2023)

Hemoglobinuria Misidentified as Hematuria: Review of Discolored Urine and Paroxysmal Nocturnal Hemoglobinuria
por: Veerreddy, Prashant
Publicado: (2013)

A Case of Paroxysmal Cold Hemoglobinuria Possessing Moderate Paroxysmal Nocturnal Hemoglobinuria-Type Erythrocytes
por: Sugimoto, Takeshi, et al.
Publicado: (2021)

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France
por: Wojciechowski, Piotr, et al.
Publicado: (2023)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_p98nrqln60krqr7ok8o1cu2nmd